PGHH
Procter & Gamble Hygiene And Health Care Limited
Each stock's 10,000-path forecast, rendered as light.
Procter & Gamble Hygiene And Health Care Limited (PGHH) Stock Analysis & Case Study
Is PGHH a good buy? The data-driven verdict.
Procter & Gamble Hygiene And Health Care Limited (PGHH) trades at ₹8,497,on the numbers it screens attractive, a Downstox Snapshot Score of 73/100.
On the numbers, Procter & Gamble Hygiene And Health Care Limited (PGHH) screens attractive, a Downstox Snapshot Score of 73/100, weighing premium at 34.9× earnings, ROE of 115.0%, a 64% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
PGHH fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How PGHH ranks against the 2,373 companies in our screener
- PGHH's market cap of 27,582 Cr ranks in the 87th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PGHH's book value of ₹232 ranks in the 75th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PGHH's promoter holding of 70.6% ranks in the 76th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PGHH's 3-year profit (PAT) growth of 14.0% ranks in the 48th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PGHH's 3-year revenue growth of 3.0% ranks in the 30th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
We do not hold a debt-to-equity ratio figure for PGHH, as of 9 Aug 2026, so it is not ranked here.
Is PGHH overvalued? PGHH P/E vs peers
PGHH trades at 34.9× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
PGHH share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 9.8y of PGHH history (2%/yr drift, 20%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| PGHH 2027 | ₹7,021 | ₹9,160 | ₹11,951 | +8% |
| PGHH 2028 | ₹6,817 | ₹9,875 | ₹14,305 | +16% |
| PGHH 2029 | ₹6,789 | ₹10,646 | ₹16,695 | +25% |
| PGHH 2030 | ₹6,848 | ₹11,477 | ₹19,234 | +35% |
| PGHH 2031 | ₹6,950 | ₹12,373 | ₹22,026 | +46% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability PGHH goes up, or doubles?
The bull case for PGHH
- PGHH's return on equity of 115.0% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PGHH's return on capital employed of 157.0% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PGHH's dividend yield of 2.7% ranks in the 92nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A 10,000-path probability model puts a 64% chance the price is higher in a year, with a median target of ₹9,160 (+8%).
- Relatively low volatility (20%/yr), a steadier ride than the typical mid/small-cap.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹16,695.
The bear case & risks
- PGHH's P/E of 34.9x is lower than 40% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- A steep 36.6× price-to-book means most of the value is intangible/expectations, not assets on the books.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹6,789.
PGHH volatility & expected range, how bumpy is the ride?
Over the last 9.8 years PGHH compounded at 2%/year with annualized volatility of 20%. That volatility implies a 1-year 80% range of ₹7,021-₹11,951, the honest backbone behind any single price target.
PGHH price forecast, the full 60-month probability fan
PGHH price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds PGHH hits common targets within the simulated horizon?
Full multi-horizon detail on the PGHH price target & forecast page.
PGHH Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. PGHH scores 6/8, mixed financial health.
PGHH MTF margin & leverage across 11 brokers
Margin Trading Facility lets you buy PGHH with part of the capital. Lower margin % = higher leverage. Rates compared across 11 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| ZerodhaCHEAPEST | 26.50% | 3.8× |
| GrowwCHEAPEST | 26.50% | 3.8× |
| DhanCHEAPEST | 26.50% | 3.8× |
| Kotak Neo | 30.03% | 3.3× |
| Paytm Money | 36.50% | 2.7× |
| PocketfulCHEAPEST | 26.50% | 3.8× |
| Fyers | 27.03% | 3.7× |
| Anand RathiCHEAPEST | 26.50% | 3.8× |
| Bajaj Broking | 27.00% | 3.7× |
| Share IndiaCHEAPEST | 26.50% | 3.8× |
Compare every broker on the PGHH MTF page.
About Procter & Gamble Hygiene And Health Care Limited: sector, index & market-cap context
Procter & Gamble Hygiene And Health Care Limited (PGHH) is a mid-cap NSE-listed company, with a market capitalisation of ₹27,582 Cr. See more stocks on our screener.
How the PGHH Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Procter & Gamble Hygiene And Health Care Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
PGHH analysis, FAQs
Is Procter & Gamble Hygiene And Health Care Limited (PGHH) a good buy?
On the numbers, Procter & Gamble Hygiene And Health Care Limited (PGHH) screens attractive, a Downstox Snapshot Score of 73/100, weighing premium at 34.9× earnings, ROE of 115.0%, a 64% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is PGHH overvalued or undervalued?
PGHH trades at 34.9× earnings, premium versus the ~22× long-run Nifty average.
What is the PGHH share price target for 2031?
PGHH's probability-weighted 2031 median target is ₹12,373, with an 80% range of ₹6,950-₹22,026 (10,000-path Monte-Carlo).
What is the probability PGHH doubles in 5 years?
The modelled probability of PGHH reaching ₹16,994 (2×) within 5 years is 24%.
What is the bull case for PGHH?
PGHH's return on equity of 115.0% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. PGHH's return on capital employed of 157.0% ranks in the top 1% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. PGHH's dividend yield of 2.7% ranks in the 92nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
What are the risks in PGHH?
PGHH's P/E of 34.9x is lower than 40% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. A steep 36.6× price-to-book means most of the value is intangible/expectations, not assets on the books.